



Patent Docket P1129R1

#24/E
MB
02/26/02

RECEIVED

FEB 05 2002

<p>In re Application of Avi J. Ashkenazi et al. Serial No.: 09/114,844 Filed: 14 July 1998 For: RTD RECEPTOR</p>	<p>Group Art Unit: 1646 Examiner: C. Kaufman</p> <p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being filed by first class mail with the United States Patent Office and addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on <u>January 14, 2002</u> <i>Diane L. Marschang</i> Diane L. Marschang</p>
--	---

TECH CENTER 1600/2900

AMENDMENT

BOX NON-FEE AMENDMENT
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This paper is being filed in response to the office action mailed July 12, 2001. Entry of the amendment below and consideration of the remarks herein are respectfully requested.

IN THE CLAIMS:

1. (Twice Amended) Isolated RTD polypeptide having at least 80% amino acid sequence identity with RTD polypeptide comprising amino acid residues 1 to 386 of Fig. 1A (SEQ ID NO:1), wherein said isolated RTD polypeptide inhibits Apo-2 ligand induced apoptosis in a mammalian cell or binds Apo-2 ligand.

2. (Once Amended) The RTD polypeptide of claim 1 wherein said RTD polypeptide has at least 90% amino acid sequence identity.

3. (Once Amended) The RTD polypeptide of claim 2 wherein said RTD polypeptide has at least 95% amino acid sequence identity.